GE’s $21.4 Billion Deal With Danaher Likely to Miss 2019 Close

Oct. 21, 2019, 3:39 PM

General Electric Co. probably won’t complete the $21.4 billion sale of a health-care business to Danaher Corp. this year as planned, pushing off a much-needed payday for the ailing manufacturer.

The deal should close in early 2020 as the companies continue to seek regulatory approval, Danaher Chief Executive Officer Thomas Joyce said Monday in a statement. The comment came as Danaher said it sold several life-sciences operations for $750 million to help get the GE bio-pharmaceutical deal over the finish line.

“While timing around meeting all closing conditions, including regulatory approvals, is still uncertain, we remain very encouraged by ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.